ZAGBEMIZ
Live / Registered — Registered (as of 14 Jan 2025)
What this means for you
Registered since 14 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98339914
- Registration number
- 7649392
- Mark type
- Stylized text
- Filed
- 03 Jan 2024
- Published for opposition
- 17 Sept 2024
- Registered
- 14 Jan 2025
- Attorney of record
- Jonathan M. Rixen
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular diseases, hematologic diseases, neurological diseases, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; pharmaceutical preparations and substances for the treatment of viral diseases, metabolic diseases, endocrine diseases, musculoskeletal diseases, cardiovascular diseases, hematologic diseases, cardiopulmonary diseases, genitourinary diseases, sexual dysfunction, oncological diseases, hepatological diseases, ophthalmic diseases, respiratory diseases, neurological diseases, gastrointestinal diseases, hormonal diseases, dermatological diseases, coagulation disorders, diseases of the blood and blood-forming organs, psychiatric and immune system related diseases and disorders, congenital bleeding disorders and acquired bleeding disorders, disorders due to a deficiency of a coagulation factor, disorders due to the presence of acquired inhibitors to a coagulation factor, hematologic disorders, hemorrhagic disorders, Von Willebrands' disease, disorders resulting from anticoagulant therapy with a vitamin-K antagonist, hereditary platelet disorders, vitamin K epoxide reductase C1 deficiency, gamma-carboxylase deficiency, bleeding associated with trauma, injury, and surgery, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated intravascular coagulation (DIC), Bernard Soulier syndrome, Glanzman thromblastemia, storage pool deficiency, and hemophilia; diagnostic preparations for medical purposes; dietetic foods and beverages adapted for medical use; depuratives for the body; veterinary pharmaceutical compounds for equine use to treat conditions of the leg, hoof, ear, nose and throat; pesticides; first aid kits; dental abrasives.
Owner
- JIANGSU BIOJETAY BIOTECHNOLOGY CO., LTD., WUXI CITY, CN
- JIANGSU BIOJETAY BIOTECHNOLOGY CO., LTD., WUXI CITY, CN
- Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing, CN
- Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing, CN
Prosecution history
- 23 Jan 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 23 Jan 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 23 Jan 2025 — TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
- 23 Jan 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 23 Jan 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 14 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 11 Dec 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 17 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Sept 2024 — PUBLISHED FOR OPPOSITION
- 28 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Jul 2024 — ASSIGNED TO EXAMINER
- 18 Apr 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Jan 2024 — NEW APPLICATION ENTERED